{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:55:59Z","timestamp":1777280159134,"version":"3.51.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Cutaneous angiosarcoma is a rare, aggressive malignancy with a poor prognosis and limited evidence guiding treatment. Optimal therapy remains undefined due to disease heterogeneity and a lack of large prospective trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To assess survival outcomes across treatment modalities and clinical stages in patients with angiosarcoma using a meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A systematic search identified studies reporting treatment and outcome data for cutaneous angiosarcoma. Patient-level data from 159 patients across 9 studies were extracted. Patients were stratified into early-stage and mid\/late-stage. Statistical analyses included Kaplan\u2013Meier estimates, Cox regression, and subgroup comparisons of recurrence, metastasis, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Early-stage patients showed longer average survival\u2014as well as delayed recurrence and metastasis\u2014compared with mid\/late-stage patients; differences were not statistically significant. Tumor location was the strongest predictor of survival in advanced-stage disease, while age predicted mortality in early-stage, with younger patients having improved survival. Treatment modality and surgical type were not independently associated with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Tumor location and patient age are important prognostic factors in angiosarcoma. Treatment modality did not significantly affect survival or recurrence, supporting individualized treatment and further investigation into survival determinants.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000004867","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T23:00:10Z","timestamp":1758150010000},"page":"415-420","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Survival Outcomes in Cutaneous Angiosarcoma: A Meta Analysis"],"prefix":"10.1097","volume":"52","author":[{"given":"Aneri Bhargav","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, Irvine, California;"},{"name":"School of Medicine, University of California, Davis, Davis, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Driscoll","sequence":"additional","affiliation":[{"name":"New York Genome Center, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajay Nair","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke","family":"Horton","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janellen","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, Irvine, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"R1-20260427","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.critrevonc.2010.10.007","article-title":"Angiosarcoma: state of the art and perspectives","volume":"80","author":"Penel","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"R2-20260427","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(10)70023-1","article-title":"Angiosarcoma","volume":"11","author":"Young","year":"2010","journal-title":"Lancet Oncol"},{"key":"R3-20260427","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3892\/ol.2015.2919","article-title":"Long-term survival of a patient with scalp angiosarcoma and multiple metastases treated using combination therapy: a case report","volume":"9","author":"Jun","year":"2015","journal-title":"Oncol Lett"},{"key":"R4-20260427","first-page":"2303","article-title":"Angiosarcoma: a review of diagnosis and current treatment","volume":"9","author":"Cao","year":"2019","journal-title":"Am J Cancer Res"},{"key":"R5-20260427","doi-asserted-by":"crossref","first-page":"203","DOI":"10.7181\/acfs.2023.00409","article-title":"Current understanding of angiosarcoma: disease biology and evolving treatment","volume":"24","author":"Kim","year":"2023","journal-title":"Arch Craniofac Surg"},{"key":"R6-20260427","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/bjd.13110","article-title":"Chemoradiotherapy with taxane is superior to conventional surgery and radiotherapy in the management of cutaneous angiosarcoma: a multicentre, retrospective study","volume":"171","author":"Fujisawa","year":"2014","journal-title":"Br J Dermatol"},{"key":"R7-20260427","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3109\/0284186X.2014.983657","article-title":"Radiation-associated angiosarcoma after breast cancer: improved survival by excision of all irradiated skin and soft tissue of the thoracic wall? A report of six patients","volume":"54","author":"Styring","year":"2015","journal-title":"Acta Oncol"},{"key":"R8-20260427","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10549-015-3506-0","article-title":"Post-irradiation angiosarcoma of the breast: clinical presentation and outcome in a series of six cases","volume":"153","author":"Uryvaev","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"R9-20260427","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s12282-015-0630-y","article-title":"Clinicopathological features of breast angiosarcoma","volume":"23","author":"Masai","year":"2016","journal-title":"Breast Cancer"},{"key":"R10-20260427","doi-asserted-by":"crossref","first-page":"921","DOI":"10.21873\/invivo.11014","article-title":"Definitive radiation therapy for angiosarcoma of the face and scalp","volume":"30","author":"Suzuki","year":"2016","journal-title":"In Vivo"},{"key":"R11-20260427","first-page":"25","article-title":"Treatment of cutaneous angiosarcoma of the scalp and face in Chinese patients: local experience at a regional hospital in Hong Kong","volume":"24","author":"Chow","year":"2018","journal-title":"Hong Kong Med J"},{"key":"R12-20260427","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/SAP.0000000000001865","article-title":"The management and prognosis of facial and scalp angiosarcoma: a retrospective analysis of 15 patients","volume":"83","author":"Alqumber","year":"2019","journal-title":"Ann Plast Surg"},{"key":"R13-20260427","first-page":"215","article-title":"Radiation-induced angiosarcoma of the breast: case series and review of the literature","volume":"10","author":"Zakaria","year":"2018","journal-title":"Facts Views Vis Obgyn"},{"key":"R14-20260427","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1111\/1346-8138.15381","article-title":"Pazopanib as a potential chemotherapy for cutaneous angiosarcoma: a case series of 10 patients from a single institution","volume":"47","author":"Fujiwara","year":"2020","journal-title":"J Dermatol"},{"key":"R21-20260427","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0970-0358.53023","article-title":"Angiosarcoma of the scalp","volume":"42","author":"Gupta","year":"2009","journal-title":"Indian J Plast Surg"},{"key":"R22-20260427","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.3390\/cancers13194816","article-title":"Genomic landscape of angiosarcoma: a targeted and immunotherapy biomarker analysis","volume":"13","author":"Espejo Freire","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R23-20260427","doi-asserted-by":"crossref","first-page":"114188","DOI":"10.1016\/j.ejca.2024.114188","article-title":"The challenge of running trials in advanced angiosarcoma: a systematic review of the literature from EORTC\/STBSG to guide the development of angiosarcoma-specific trials","volume":"207","author":"Dufresne","year":"2024","journal-title":"Eur J Cancer"},{"key":"R24-20260427","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/annonc\/mdy464","article-title":"An adaptive population enrichment phase III trial of TRC105 and pazopanib versus pazopanib alone in patients with advanced angiosarcoma (TAPPAS trial)","volume":"30","author":"Mehta","year":"2019","journal-title":"Ann Oncol"},{"key":"R25-20260427","first-page":"abstr 11512","article-title":"Alliance A091902: a multicenter randomized phase II trial of paclitaxel with or without nivolumab in patients with advanced angiosarcoma","volume":"42","author":"Grilley-Olson Jason","year":"2024","journal-title":"J Clin Oncol"},{"key":"R26-20260427","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaoncol.2021.3547","article-title":"Efficacy and safety of TRC105 plus pazopanib vs pazopanib alone for treatment of patients with advanced angiosarcoma: a randomized clinical trial","volume":"8","author":"Jones","year":"2022","journal-title":"JAMA Oncol"},{"key":"R27-20260427","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hed.21513","article-title":"Outcomes after definitive treatment for cutaneous angiosarcoma of the face and scalp","volume":"33","author":"Guadagnolo","year":"2011","journal-title":"Head Neck"},{"key":"R28-20260427","first-page":"4602","article-title":"Angiosarcoma of the breast, the unknown\u2014a review of the current literature","volume":"9","author":"Enrico","year":"2020","journal-title":"Transl Cancer Res"},{"key":"R29-20260427","doi-asserted-by":"crossref","first-page":"e24413","DOI":"10.1016\/j.heliyon.2024.e24413","article-title":"Angiosarcoma of the breast: a review","volume":"10","author":"An","year":"2024","journal-title":"Heliyon"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T08:03:13Z","timestamp":1777276993000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004867","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}